The U.S. IPO market printed its largest volume week since early 2022, with at least three companies pricing offerings totaling approximately $380 million across biotech therapeutics and defense technology. Seaport Therapeutics filed terms for a $201 million offering, Hemab Therapeutics set a $100 million target, and HawkEye 360 disclosed initial pricing plans for its defense satellite offering. The simultaneous launches mark the first multi-sector IPO week since Federal Reserve rates crossed 5.25% in mid-2023.
Seaport Therapeutics, developing neuropsychiatric compounds including a GABA-A modulator for major depressive disorder, set terms this week with pricing expected before Friday's close. Hemab Therapeutics, focused on clotting disorder therapies, filed simultaneously with a similar timeline. HawkEye 360, a radio-frequency satellite reconnaissance provider serving U.S. defense and commercial clients, detailed pricing parameters through Aviation Week without disclosing exact range. The offerings span three sectors—CNS therapeutics, hematology, and dual-use space infrastructure—indicating institutional appetite beyond single-theme momentum.
The breadth matters more than the aggregate dollar volume. IPO markets reopened sporadically in 2024 with isolated large-cap technology deals, but sustained multi-week activity across mid-cap names and diverse sectors has been absent since Q1 2022. Seaport's neuropsych focus and Hemab's clotting work reflect renewed willingness to underwrite pre-revenue biotech, a subsector that saw zero institutional IPOs during the 18 months ending September 2024. HawkEye's defense positioning captures dual trends: Pentagon modernization budgets and commercial satellite demand from infrastructure monitoring and maritime tracking clients. The three simultaneous pricings suggest syndicate desks believe clearing prices exist across risk profiles, not just in momentum names.
For allocators, the tell is what follows in March and April. If Seaport and Hemab trade above offer within 30 days and HawkEye sustains institutional book-building through pricing, the queue of filed-but-waiting biotechs—approximately 22 names per Renaissance Capital's pipeline—will accelerate toward market. Private biotechs that raised Series C rounds in 2021-2022 at $800M-$1.2B post-money valuations face 2025 cash exhaustion; public markets reopening permits down-round but survivable IPOs. Defense tech names will watch HawkEye's reception; at least four venture-backed space and autonomy companies delayed 2024 processes awaiting sector proof-of-concept.
Watch Seaport's first-day close and whether it holds or fades by day five. Biotech IPO durability, not pop, determines follow-on supply. HawkEye's final pricing range and whether lead orders include sovereign wealth or purely domestic institutions will clarify if defense tech can access the same re-opened capital base. The syndicate banks on all three offerings—not yet fully disclosed—will indicate if bulge brackets are committing capital or farming mid-tier deals to regional desks.